These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28447953)

  • 1. Short duration of direct-acting antivirals for acute HCV infection.
    Yu ML
    Lancet Infect Dis; 2017 May; 17(5):481-482. PubMed ID: 28447953
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct-acting antivirals for acute HCV: how short can we go?
    Martinello M; Grebely J; Matthews GV
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):316-318. PubMed ID: 28397692
    [No Abstract]   [Full Text] [Related]  

  • 3. A new era of therapy for hepatitis C virus infection.
    Nyalakonda H; Utay NS
    Curr Opin Infect Dis; 2015 Oct; 28(5):471-8. PubMed ID: 26203851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus therapeutic development: in pursuit of "perfectovir".
    Dore GJ; Feld JJ
    Clin Infect Dis; 2015 Jun; 60(12):1829-36. PubMed ID: 25761867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance-Associated Substitutions in Short Duration of Interferon-Free Direct-Acting Antivirals for Hepatitis C.
    Yu ML
    Gastroenterology; 2017 Sep; 153(3):867. PubMed ID: 28781223
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease.
    Maruyama A; Partovi N; Yoshida EM; Erb SR; Azalgara VM; Hussaini T
    Nephrol Dial Transplant; 2017 Jan; 32(1):35-41. PubMed ID: 26481484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges.
    Thompson A; Patel K; Tillman H; McHutchison JG
    J Hepatol; 2009 Jan; 50(1):184-94. PubMed ID: 19022518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus infection in maintenance hemodialysis patients: recommendations for diagnostics and treatment.
    Dzekova-Vidimliski P; Sikole A
    Int J Artif Organs; 2017 Feb; 39(12):590-595. PubMed ID: 28165585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct acting antivirals. Authors' reply.
    Mangia A; Piazzolla V; Santoro R
    Aliment Pharmacol Ther; 2017 Sep; 46(6):629-630. PubMed ID: 28805326
    [No Abstract]   [Full Text] [Related]  

  • 10. Direct-acting antivirals response in an acute nosocomial genotype 1b HCV outbreak.
    Benson AA; Wolf D; Lederman N; Safadi R
    Dig Liver Dis; 2018 Jun; 50(6):630-632. PubMed ID: 29628358
    [No Abstract]   [Full Text] [Related]  

  • 11. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
    Pár A
    Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Direct Acting Antivirals for Treatment of Hepatitis C Infection in Patients with Advanced Liver Disease].
    Chung WJ
    Korean J Gastroenterol; 2016 Jan; 67(1):58-60. PubMed ID: 27213201
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals.
    Zeremski M; Martinez AD; Talal AH
    Clin Infect Dis; 2014 Mar; 58(6):880-2. PubMed ID: 24336913
    [No Abstract]   [Full Text] [Related]  

  • 14. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
    Vachon ML; Dieterich DT
    Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current progress in host innate and adaptive immunity against hepatitis C virus infection.
    Shi J; Li Y; Chang W; Zhang X; Wang FS
    Hepatol Int; 2017 Jul; 11(4):374-383. PubMed ID: 28643186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents.
    Kyvernitakis A; Mahale P; Popat UR; Jiang Y; Hosry J; Champlin RE; Torres HA
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):717-722. PubMed ID: 26712592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
    Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals?
    Visentini M; Fiorilli M; Casato M
    Expert Rev Hematol; 2017 Aug; 10(8):719-727. PubMed ID: 28675071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection.
    Thibault V
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):145-147. PubMed ID: 29371018
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.